Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 19   Выпуск 2   Год 2024
Хамад Али Хамад1, Хаммад Халаф Саид2, Талиб Хаммад Хусейн2, Абдалвахаб Бдеви Хусейн1, Нур Фариша Мд Хашим3

Обнаружение потенциальных терапевтических целей при рецидиве рака молочной железы: дифференциально экспрессируемые гены у пациентов после операции

Математическая биология и биоинформатика. 2024;19(2):276-292.

doi: 10.17537/2024.19.276.

Список литературы

  1. Anayyat U., Ahad F., Muluh T.A., Zaidi S.A.A., Usmani F., Yang H., Li M., Hassan H.A., Wang X. Immunotherapy: Constructive Approach for Breast Cancer Treatment. Breast Cancer: Targets and Therapy. 2023;15:925–951 doi: 10.2147/BCTT.S424624
  2. Momenimovahed Z., Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer: Targets and Therapy. 2019;11:51–164. doi: 10.2147/BCTT.S176070
  3. Pasculli B., Barbano R., Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. Semin. Cancer Biol. 2018;51:22–35. doi: 10.1016/j.semcancer.2018.01.007
  4. Rahman M.M., Brane A.C., Tollefsbol T.O. MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer. Cells. 2019;8. Article No. 1214. doi: 10.3390/cells8101214
  5. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 2024;74(3):229–263. doi: 10.3322/caac.21834
  6. Arnold M., Morgan E., Rumgay H., Mafra A., Singh D., Laversanne M., Vignat J., Gralow J.R., Cardoso F., Siesling S., et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66(15–23). doi: 10.1016/j.breast.2022.08.010
  7. Hwang K.T., Kim J., Jung J., Chang J.H., Chai Y.J., Oh S.W., Oh S., Kim Y.A., Park S.B., Hwang K.R. Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: A population-based study using SEER database. Clin. Cancer Res. 2019;25(6):1970–1979. doi: 10.1158/1078-0432.CCR-18-2782
  8. Tsang JY, Gary MT. Molecular classification of breast cancer. Advances in Anatomic Pathology. 2020;1(27):27–35. doi: 10.1097/PAP.0000000000000232
  9. Prat A., Pineda E., Adamo B., Galván P., Fernández A., Gaba L., Díez M., Viladot M., Arance A., Muñoz M. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015;1(24):S26–S35. doi: 10.1016/j.breast.2015.07.008
  10. Kamińska M., Ciszewski T., Łopacka-Szatan K., Miotła P., Starosławska E. Breast cancer risk factors. Menopause Rev. 2015;14(3):196–202. doi: 10.5114/pm.2015.54346
  11. Zhao P., Xia N., Zhang H., Deng T. The Metabolic Syndrome Is a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis. Obes. Facts. 2020;13(4):384–396. doi: 10.1159/000507554
  12. Azadnajafabad S., Moghaddam S.S., Keykhaei M., Shobeiri P., Rezaei N., Ghasemi E., Mohammadi E., Ahmadi N., Ghamari A., Shahin S., et al. Expansion of the quality of care index on breast cancer and its risk factors using the global burden of disease study 2019. Cancer Med. 2023;12(2):1729–1743. doi: 10.1002/cam4.4951
  13. Schünemann H.J., Lerda D., Quinn C., Follmann M., Alonso-Coello P., Rossi P.G., Lebeau A., Nyström L., Broeders M., Ioannidou-Mouzaka L., et al. Breast cancer screening and diagnosis: A synopsis of the European Breast Guidelines. Ann. Intern. Med. 2020;172(1):46–56. doi: 10.7326/M19-2125
  14. Waks AG, Winer EP. Breast cancer treatment: A review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323
  15. Bick U., Trimboli R.M., Athanasiou A., Balleyguier C., Baltzer P.A., Bernathova M., Borbély K., Brkljacic B., Carbonaro L.A., Clauser P., et al. Image-guided breast biopsy and localisation: Recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights into Imaging. 2020;11. Article No. 12. doi: 10.1186/s13244-019-0803-x
  16. Louro J., Román M., Posso M., Comerma L., Vidal C., Saladié F., Alcantara R., Sanchez M., Quintana M.J., Del Riego J. et al. Differences in breast cancer risk after benign breast disease by type of screening diagnosis. The Breast. 2020;54(1):343–348. doi: 10.1016/j.breast.2020.09.005
  17. Tripathi K., Yadav R., Maurya S.K. A comparative study between fine-needle aspiration cytology and core needle biopsy in diagnosing clinically palpable breast lumps. Cureus. 2022;14. Article No. e27709. doi: 10.7759/cureus.27709
  18. Riis M. Modern surgical treatment of breast cancer. Ann. Med. Surg. 2020;56:95–107. doi: 10.1016/j.amsu.2020.06.016
  19. Kaidar-Person O., Offersen B.V., Boersma L.J., de Ruysscher D., Tramm T., Kühn T., Gentilini O., Mátrai Z., Poortmans P. A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges. The Breast. 2021;56:42–52. doi: 10.1016/j.breast.2021.02.004
  20. Labrosse J., Osdoit M., Hamy A.S., Coussy F., Pierga J.Y., Reyal F., Laas E. Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. PLoS ONE. 2020;15(6). Article No. e0234173. doi: 10.1371/journal.pone.0234173
  21. Buzdar AU. Preoperative chemotherapy treatment of breast cancer—a review. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2007;110(11):2394–2407. doi: 10.1002/cncr.23083
  22. Chen X., Liu L., Wang Y., Liu B., Zeng D., Jin Q., Li M., Zhang D., Liu Q., Xie H. Identification of breast cancer recurrence risk factors based on functional pathways in tumor and normal tissues. Oncotarget. 2016;8(13):20679–20694. doi: 10.18632/oncotarget.11557
  23. Rueda O.M., Sammut S.J., Seoane J.A., Chin S.F., Caswell-Jin J.L., Callari M., Batra R., Pereira B., Bruna A., Ali H.R., et al. Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature. 2019;567(7748):399–404. doi: 10.1038/s41586-019-1007-8
  24. Ordaz-Ramos A., Tellez-Jimenez O., Vazquez-Santillan K. Signaling pathways governing the maintenance of breast cancer stem cells and their therapeutic implications. Front. Cell Dev. Biol. 2023;11. Article No. 1221175. doi: 10.3389/fcell.2023.1221175
  25. Hamad H.A., Gopalsamy B., Kqueen C.Y., Hashim N.F.M., Potential Ability of Phytochemical in Inhibition of Invadopodia Formation and HIF-1α in Cancer Metastasis. Malaysian Journal of Medicine & Health Sciences. 2019;15:71–80.
  26. Kamdje A.H.N., Etet P.F.S., Vecchio L., Muller J.M., Krampera M., Lukong K.E. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–2856. doi: 10.1016/j.cellsig.2014.07.034
  27. Ahmad A. Pathways to breast cancer recurrence. International Scholarly Research Notices. 2013;2013(1). Article No. 290568. doi: 10.1155/2013/290568
  28. Jabbar FA., AlChalabi R., AL-Tarboolee AY., Shaban SA., Suleiman AA. Alternative Splicing in Pancreatic Ductal Adenocarcinoma Leads to Dysregulated Immune System. Mathematical Biology and Bioinformatics. 2024;19(1):15–35 doi: 10.17537/2024.19.15
  29. Alaimo S., Di Maria A., Shasha D., Ferro A., Pulvirenti A. TACITuS: transcriptomic data collector, integrator, and selector on big data platform. BMC Bioinformatics. 2019;20(9). Article No. 366. doi: 10.1186/s12859-019-2912-4
  30. Garcia-Moreno A., López-Domínguez R., Villatoro-García J.A., Ramirez-Mena A., Aparicio-Puerta E., Hackenberg M., Pascual-Montano A., Carmona-Saez P., Functional Enrichment Analysis of Regulatory Elements. Biomedicines. 2022;10. Article No. 590. doi: 10.3390/biomedicines10030590
  31. Szklarczyk D., Kirsch R., Koutrouli M., Nastou K., Mehryary F., Hachilif R., Gable A.L., Fang T., Doncheva N.T., Pyysalo S,. et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–D646. doi: 10.1093/nar/gkac1000
  32. Riggio A.I., Varley K.E., Welm A.L. The lingering mysteries of metastatic recurrence in breast cancer. Br. J. Cancer. 2021;124:13–26. doi: 10.1038/s41416-020-01161-4
  33. Baghban R., Roshangar L., Jahanban-Esfahlan R., Seidi K., Ebrahimi-Kalan A., Jaymand M., Kolahian S., Javaheri T., Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal. 2020;18(1). Article No. 59. doi: 10.1186/s12964-020-0530-4
  34. Khalaf K., Hana D., Chou J.T.T., Singh C., Mackiewicz A., Kaczmarek, M. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance. Front. Immunol. 2021;12. Article No. 656364. doi: 10.3389/fimmu.2021.656364
  35. Mares-Quiñones M.D., Galán-Vásquez E., Pérez-Rueda E., Pérez-Ishiwara D.G., Medel-Flores M.O., Gómez-García M.D.C. Identification of modules and key genes associated with breast cancer subtypes through network analysis. Sci. Rep. 2024;14. Article No. 12350. doi: 10.1038/s41598-024-61908-4
  36. Jiang Y., Chen F., Ren X., Yang Y., Luo J., Yuan J., Yuan J., Tong, Q. RNA-Binding Protein COL14A1, TNS1, NUSAP1 and YWHAE Are Valid Biomarkers to Predict Peritoneal Metastasis in Gastric Cancer. Front. Oncol. 2022;12. Article No. 830688. doi: 10.3389/fonc.2022.830688
  37. Wu Z.H., Zhang Y.J., Yue J.X., Zhou T. Comprehensive Analysis of the Expression and Prognosis for SFRPs in Breast Carcinoma. Cell Transplant. 2020. Article No. 29. doi: 10.1177/0963689720962479
  38. Motrich R.D., Castro G.M., Caputto, B.L. Old Players with a Newly Defined Function: Fra-1 and c-Fos Support Growth of Human Malignant Breast Tumors by Activating Membrane Biogenesis at the Cytoplasm. PLoS ONE. 2013;8(1). Article No. e53211. doi: 10.1371/journal.pone.0053211
  39. Nulali J., Zhan M., Zhang K., Tu P., Liu Y., Song H. Osteoglycin: An ECM Factor Regulating Fibrosis and Tumorigenesis. Biomolecules. 2022;12(11). Article No. 1674. doi: 10.3390/biom12111674
  40. Bae H., Kim B., Lee H., Lee S., Kang H.S., Kim, S.J. Epigenetically regulated Fibronectin leucine rich transmembrane protein 2 (FLRT2) shows tumor suppressor activity in breast cancer cells. Sci. Rep. 2017;7. Article No. 272. doi: 10.1038/s41598-017-00424-0
  41. Ahmed K.A., Hasib T.A., Paul S.K., Saddam M., Mimi A., Saikat A.S.M., Faruque H.A., Rahman M.A., Uddin M.J., Kim, B. Potential Role of CCN Proteins in Breast Cancer: Therapeutic Advances and Perspectives. Curr. Oncol. 2021;28(6):4972–4985. doi: 10.3390/curroncol28060417
  42. Harikrishnan K., Joshi O., Madangirikar S., Balasubramanian N. Cell Derived Matrix Fibulin-1 Associates With Epidermal Growth Factor Receptor to Inhibit Its Activation, Localization and Function in Lung Cancer Calu-1 Cells. Front. Cell Dev. Biol. 2020;8. Article No. 522. doi: 10.3389/fcell.2020.00522
  43. Shan N.L., Minden A., Furmanski P., Bak M.J., Cai L., Wernyj R., Sargsyan D., Cheng D., Wu R., Kuo H.C.D., et al. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds. Cancer Prev. Res. 2020;13:673–686. doi: 10.1158/1940-6207.CAPR-19-0566
  44. Pei G., Lan Y., Lu W., Ji L., Hua Z.C. The function of FAK/CCDC80/E-cadherin pathway in the regulation of B16F10 cell migration. Oncol. Lett. 2018;16(4):4761–4767. doi: 10.3892/ol.2018.9159
  45. Miricescu D., Totan A., Stanescu-Spinu I.I., Badoiu S.C., Stefani C., Greabu, M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int. J. Mol. Sci. 2021;22. Article No. 173. doi: 10.3390/ijms22010173
  46. Abreu de Oliveira W.A., El Laithy Y., Bruna A., Annibali D., Lluis F. Wnt Signaling in the Breast: From Development to Disease. Front. Cell Dev. Biol. 2022;10. Article No. 884467. doi: 10.3389/fcell.2022.884467
  47. You M., Xie Z., Zhang N., Zhang Y., Xiao D., Liu S., Zhuang W., Li L., Tao Y. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct. Target. Ther. 2023;8. Article No. 196. doi: 10.1038/s41392-023-01442-3
  48. Hamad H.A., Enezei H.H., Alrawas A., Zakuan N.M., Abdullah N.A., Cheah Y.K., Hashim N.F.M. Identification of Potential Chemical Substrates as Fuel for Hypoxic Tumors That May Be Linked to Invadopodium Formation in Hypoxia-Induced MDA-MB-231 Breast-Cancer Cell Line. Molecules. 2020;25(17). Article No. 3876. doi: 10.3390/molecules25173876
  49. Popova N.V., Jücker M. The Functional Role of Extracellular Matrix Proteins in Cancer. Cancers. 2022;14(1). Article No. 238. doi: 10.3390/cancers14010238
  50. Wang W., Wang X., Yao F., Huang C. Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer. Int. J. Mol. Sci. 2022;23(20). Article No. 12270. doi: 10.3390/ijms232012270
  51. Meysami M., Rahaie M., Ebrahimi A., Samiee, F. Four Matrix Metalloproteinase genes involved in murine breast cancer affected by ginger extract. Gene Rep. 2021;25. Article No. 101332. doi: 10.1016/j.genrep.2021.101332
  52. Jiang Y., Wang B., Li J.K., Li S.Y., Niu R.L., Fu N.Q., Zheng J.J., Liu G., Wang Z.L. Collagen fiber features and COL1A1: are they associated with elastic parameters in breast lesions, and can COL1A1 predict axillary lymph node metastasis? BMC Cancer. 2022;22(1). Article No. 1004. doi: 10.1186/s12885-022-10092-7
  53. Li X., Sun X., Kan C., Chen B., Qu N., Hou N., Liu Y., Han F. COL1A1: A novel oncogenic gene and therapeutic target in malignancies. Pathol. Res. Pract. 2022;236. Article No. 154013. doi: 10.1016/j.prp.2022.154013

 
Содержание
Оригинальная статья
Мат. биол. и биоинф.
2024;19(2):276-292
doi: 10.17537/2024.19.276
опубликована на англ. яз.

Аннотация (англ.)
Аннотация (рус.)
Полный текст (англ., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2024